Launch of TetraGraph Xcom interface to electronic medical records
News: Uppsala, August 5, 2022. Senzime announces today the launch of TetraGraph® Xcom, a solution that enables communication between the TetraGraph® and Philips Capsule Medical Device Information Platform (MDIP). The integration enables the electronic transmission of neuromuscular data from the TetraGraph® directly to the patient's medical record.
Philips Capsule is a leading global provider of medical device integration and information solutions for healthcare providers. Founded more than two decades ago and with over 2,700 hospital sites and 20 million patients connected annually, Philips Capsule is the standard for medical device integration and is expanding the boundaries of system interoperability, patient monitoring, and clinical surveillance.
Senzime’s TetraGraph® system helps anesthesia providers improve patient care, eliminate complications, and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery.
The new TetraGraph® Xcom interface and the Philips Capsule Medical Device Information Platform (MDIP) connects almost all existing medical devices and EMRs in hospitals through a vendor-neutral system and is designed to help improve workflow and save time. Interconnected medical devices are essential resources in the delivery of patient care.
Pia Renaudin, CEO of Senzime states, " With our new Xcom interface the TetraGraph® can transmit critical patient information and displayed it on a wide range of EMR- and EHR-systems worldwide. Our smart new connector and partnership with Philips Capusle enables healthcare providers to standardize the monitoring of patients with paralytic drugs using the Senzime TetraGraph® system.”
This interface is in line with Senzime’s vision to standardize patient monitoring with the TetraGraph®-system when neuromuscular blocking drugs are used.
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). www.senzime.com